Disitamab vedotin
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) , and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity[1].
Product Specifications
CAS Number
2136633-23-1
Product Name Alternative
RC48
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; EGFR
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/disitamab-vedotin.html
Purity
99.0
Solubility
H2O
Smiles
[Disitamabvedotin]
Molecular Weight
149000 (average)
References & Citations
[1]Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81 (16) :1929-1935.|[2]Jiang J, et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. |[3]Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with anti-PD- (L) 1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191 (1) :51-61.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Launched
Isoform
ErbB2/HER2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
